BioAgna - Company finances
|
EUR
|
2021
From: 2021-03-12
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 12,078 | 35,782 | 22,523 | 37,817 | 47,580 |
| Profit before tax | 2,547 | 5,386 | -10,560 | -3,984 | -2,143 |
| Net profit | 2,547 | 5,148 | -10,560 | -3,984 | -2,143 |
| Equity | 2,547 | 4,491 | -6,069 | -10,053 | -12,196 |
| Liabilities | - | 1,933 | 10,328 | 20,015 | 25,763 |
| Non-current assets | 0 | 0 | 0 | 3,675 | 2,940 |
| Current assets | 3,523 | 6,424 | 4,259 | 6,287 | 10,627 |
| Total assets | 3,523 | 6,424 | 4,259 | 9,962 | 13,567 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 3,351 | 1,248 | 2,174 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +196.3% | -37.1% | +67.9% | +25.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 72.3% | 80.1% | -247.9% | -40.0% | -15.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 114.6% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 21.1% | 14.4% | -46.9% | -10.5% | -4.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 21.1% | 15.1% | -46.9% | -10.5% | -4.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.4 | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 8,052 | 40,894 | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
BioAgna - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-03-04 | 2025-03-31 | 80.40 |
| 2025-03-03 | 2025-03-03 | 72.45 |
| 2025-03-01 | 2025-03-02 | 80.40 |
| 2025-02-27 | 2025-02-28 | 7.95 |
| 2025-02-11 | 2025-02-26 | 72.45 |
| 2025-02-10 | 2025-02-10 | 64.50 |
| 2025-02-01 | 2025-02-09 | 72.45 |
| 2025-01-02 | 2025-01-28 | 64.50 |
| 2024-12-03 | 2024-12-08 | 64.50 |
| 2024-11-04 | 2024-11-20 | 64.50 |
| 2024-10-01 | 2024-10-28 | 64.50 |
| 2024-09-03 | 2024-09-03 | 64.50 |
| 2024-03-01 | 2024-03-19 | 4.34 |
| 2024-02-01 | 2024-02-29 | 2.34 |
| 2024-01-03 | 2024-01-31 | 0.34 |
| 2023-11-03 | 2023-12-31 | 0.34 |
| 2023-10-03 | 2023-10-31 | 0.34 |
| 2023-07-03 | 2023-09-30 | 0.34 |
| 2023-05-02 | 2023-06-30 | 0.34 |
| 2023-04-03 | 2023-04-30 | 0.34 |
| 2023-01-03 | 2023-03-31 | 0.34 |
| 2022-11-03 | 2022-12-31 | 0.34 |
| 2022-09-19 | 2022-09-30 | 152.85 |
| 2022-09-16 | 2022-09-18 | 303.67 |
| 2022-09-01 | 2022-09-15 | 203.80 |
| 2022-08-29 | 2022-08-31 | 152.85 |
| 2022-08-23 | 2022-08-28 | 177.77 |
| 2022-08-02 | 2022-08-22 | 165.63 |
| 2022-07-25 | 2022-08-01 | 114.68 |
| 2022-07-18 | 2022-07-24 | 114.67 |
| 2022-07-01 | 2022-07-17 | 102.53 |
| 2022-06-16 | 2022-06-30 | 51.58 |
| 2022-06-01 | 2022-06-15 | 39.44 |
| 2022-05-03 | 2022-05-10 | 27.30 |
| 2022-04-01 | 2022-04-18 | 15.16 |
| 2022-03-01 | 2022-03-13 | 3.11 |
| 2021-11-04 | 2021-11-08 | 44.81 |
| 2021-10-18 | 2021-10-27 | 8.86 |
| 2021-10-01 | 2021-10-11 | 41.05 |
BioAgna - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
BioAgna, MB (code 305713925) is a Small partnership engaged in the manufacture of soft drinks and bottled waters. In the latest financial year, 2025, the company generated revenue of €47.6K, up 25.8% year on year and 111.2% higher than in 2023. Over the same period, profitability improved but remained negative: net loss narrowed from €10.6K in 2023 to €4.0K in 2024 and €2.1K in 2025, with the profit margin moving from -46.9% to -10.5% and then to -4.5%. The balance sheet expanded from €4.3K in assets in 2023 to €13.6K in 2025, supported by higher short-term assets of €10.6K and long-term assets of €2.9K. Liabilities rose from €10.3K to €25.8K, while equity remained negative and declined to -€12.2K in 2025. Asset turnover was 3.51x in 2025, indicating relatively efficient use of assets for revenue generation. Revenue per employee stood at €23.8K, while profit per employee was -€1.1K.